The FDA has cleared the first blood-based test to aid in diagnosing Alzheimer’s disease, offering a less invasive alternative to positron emission tomography scans and cerebrospinal fluid testing for cognitively impaired patients.
Researchers found that breast-conserving treatment provided long-term survival outcomes comparable to mastectomy in patients with breast cancer and BRCA1 or BRCA2 pathogenic variants.
FDA approves Brekiya®, a dihydroergotamine mesylate autoinjector for the acute treatment of migraine with or without aura and cluster headaches in adults.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A systematic review reveals that GLP-1 receptor agonists not only address psychotropic-induced metabolic disorders but also may positively impact mental wellbeing.